Full Coverage

Q1 financial results reported for DOR BioPharma Inc

m2.com
May 19, 2008
        
Story Timeline:  197 days

Published in M2 EquityBites on Monday, 19 May 2008 at 15:53 GMT DOR BioPharma Inc (OTCBB:DORB.OB), a biopharmaceutical company, reported on 16 May its financial results for the first quarter ended 31 March 2008. The company's revenues for the first quarter were USD0.7m, an increase when compared... [read full story]                    

Add Comment
Latest article on this story:

DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy

 redorbit.com May 22, 2008
First article on this story:

DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy

 tmcnet.com May 22, 2008
Selected publications with coverage of this story:
redorbit.com marketwire.com yahoo.com pharmiweb.co.uk tmcnet.com m2.com
RELATED
Found 4 documents:
                   

DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy

redorbit.com
May 22, 2008
        

Posted on: Thursday, 22 May 2008, 09:01 CDT DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments, serious gastrointestinal diseases and vaccines against certain...

                   

DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy (Marketwire)

yahoo.com
May 22, 2008
        

Thursday May 22, 8:00 am ET DOR Enters Into Letter of Intent With IDIS for Named Patient Access of orBec(R) in Europe EWING, NJ--(MARKET WIRE)--May 22, 2008 -- News ) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of...

                   

DOR BioPharma, Inc.: DOR BioPharma Provides Update on orBec(R) European Regulatory and...

marketwire.com
May 22, 2008
        

EWING, NJ (MARKET WIRE) DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments, serious gastrointestinal diseases and vaccines against certain bioterrorism agents,...

                   

DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy

tmcnet.com
May 22, 2008
        

EWING, NJ, May 22 / MARKET WIRE/ -- DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments, serious gastrointestinal diseases and vaccines against certain bioterrorism...

Related categories